Table of Contents

• 1. Website
• 2. Name of journal
• 3. Peer review process
• 4. Ownership, journal management team, and publishing credentials
• 5. Governing body
• 6. Editorial team and contact information
• 7. Copyright and licensing
• 8. Author fees
• 9. Process for the identification of and dealing with allegations of research misconduct
• 10. Publication ethics
• 11. Publishing schedule
• 12. Access
• 13. Archiving
• 14. Revenue sources
• 15. Advertising
• 16. Direct marketing

1. Website

• i. The URL address of official journal web site is https://www.e-enm.org.

• ii. 'Aims & Scope' statement: http://www.e-enm.org/about/
• The aim of Endocrinology and Metabolism (EnM) is to set high standards of medical care by providing a forum for discussion for basic, clinical, and translational researchers and clinicians on new findings in the fields of endocrinology and metabolism. EnM reports new findings and developments in all aspects of endocrinology and metabolism. The topics covered by this journal include bone and mineral metabolism, cytokines, developmental endocrinology, diagnostic endocrinology, endocrine research, dyslipidemia, endocrine regulation, genetic endocrinology, growth factors, hormone receptors, hormone action and regulation, management of endocrine diseases, clinical trials, epidemiology, molecular endocrinology, neuro- endocrinology, neuropeptides, neurotransmitters, obesity, pediatric endocrinology, reproductive endocrinology, signal transduction, the anatomy and physiology of endocrine organs (i.e., the pituitary, thyroid, parathyroid, and adrenal glands, and the gonads), and endocrine diseases (diabetes, nutrition, osteoporosis, etc.). This journal also covers results from studies undertaken over the pediatric, adult, elderly, and postmenopausal periods of life.
• iii. Readership:
  EnM is essential reading not only for those engaged in endocrine research but also for those involved in clinical practice and for those who are involved in establishment of government's policy in the field of endocrinology and metabolism.
• iv. Authorship criteria: http://www.e-enm.org/authors/authors.php
• All authors of the article should have contributed significantly according to the following four criteria: 1) substantial contributions to the concept and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the work or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors should meet the above four conditions.
• v. Duplicate submission and redundant publication: http://www.e-enm.org/authors/ethics.php
• All submitted manuscripts should be original and may not be considered by other scientific journals for publication at the same time. No part of the accepted paper should be duplicated in another scientific journal without permission from the Editorial Board. Submitted manuscripts are screened for possible plagiarism or duplicate publication by CrossCheck upon arrival. If duplicate publications related to the papers published in EnM are detected, authors will be sanctioned by requesting their institutions to assess the facts, requesting a letter to the Editor-in-Chief acknowledging the error and voluntarily withdrawing the paper, and banning the authors from publishing in EnM for up to 3 years.
• vi. pISSN: 2093-596X eISSN; 2093-5978

2. Name of journal

• The official journal title is Endocrinology and Metabolism. Abbreviated title is Endocrinol Metab (EnM).

3. Peer review process

• http://www.e-enm.org/authors/authors.php
• Submitted manuscripts are first reviewed by the journal editors. If a manuscript fails to comply with the submission guidelines or the EnM Submission Checklist, it will be rejected for review and returned to the author to be re-written and re-submitted according to the submission guidelines. All submitted manuscripts are single-blind peer-reviewed by three anonymous reviewers who are specialists in the relevant field, and the review period will not exceed 3 months. The decision of whether to publish the article will be determined based on the results of the review process, and revisions or additions will be recommended to the authors as appropriate. The Editorial Board determines whether manuscripts are acceptable. If changes are needed, the authors are recommended to revise and amend the manuscripts within 1 month.

4. Ownership and management

• i. Information about the ownership: This journal is owned by the publisher, the Korean Endocrine Society http://www.endocrinology.or.kr/eng/
• ii. Management team of a journal
• - Journal Manager:
• Won-Young Lee, Co-Editor-in-Chief of EnM, Sungkyunkwan University, Korea
• Young Joo Park, Co-Editor-in-Chief of EnM, Seoul National University, Korea
• - Manager of the Review Process:
• Han Seok Choi, Deputy Editor of EnM, Dongguk University, Korea
• Jung Hee Kim, Deputy Editor of EnM, Seoul National University, Korea
• Mee Kyoung Kim, Deputy Editor of EnM, The Catholic University, Korea
• Eun-Jung Rhee, Deputy Editor of EnM, Sungkyunkwan University, Korea
• - Statistics Editor:
• Hong-Yup Ahn, Dongguk University, Korea
• Kyungdo Han, Soongsil University, Korea
• Yong-Moon Park, National Institutes of Health, Research Triangle Park, USA
• - Manuscript Editors: Young Ji Choi, Infolumi, Seongnam; Hye Yeon Jang, Korean Endocrine Society, Seoul, Korea
• - Layout Editors: Academya Publishing Co., Korea
• - Website and JATS XML File Producers: M2Community Co., Korea

5. Governing body

• The governing body is the journal's editorial board.

6. Editorial team and contact information

• https://www.e-enm.org/about/editorial.php
• Endocrinology and Metabolism editorial office contact information
• 101-2503, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea.
• Tel: +82-2-716-2428, Fax: +82-2-714-5103
• E-mail: journal@endocrinology.or.kr, http://www.endocrinology.or.kr

7. Copyright and Licensing

• https://www.escienceediting.org/about/open_access.php
• i. Copyright policy: Copyright to all the published material is owned by the Korean Endocrine Society. Every author should agree to the copyright transfer during the submission process. The corresponding author is responsible for submitting the copyright transfer agreement to the Publisher. Permission must be obtained from the Korean Endocrine Society for any commercial use of materials.
• ii. Licensing information: This is an open-access journal distributed under the terms of the Creative Commons Attribution Non-commercial license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited for non-commercial purpose (http://creativecommons.org/licenses/by-nc/4.0/).
• iii. Deposit policy: According to the deposit policy (self-archiving policy) of Sherpa/Romeo (http://www.sherpa.ac.uk/), authors cannot archive pre-prints (i.e., pre-refereeing) but archive post-prints (i.e., final draft post-refereeing) and publisher’s version/PDF Authors can archive publisher's version/PDF.

8. Author fees

• http://www.e-enm.org/authors/processing_charge.php
• Starting in May 2022, an article processing charge will be applied for new submissions.
  All accepted manuscripts will be charged a publication fee.

	Publication Fee*
Member of the Korean Endocrine Society	$300
Non-member of the Korean Endocrine Society	$600

*Only original articles and uninvited review articles

9. Process for the identification of and dealing with allegations of research misconduct

• http://www.e-enm.org/authors/ethics.php
• EnM is a member of Cross-Check plagiarism detection initiative and takes all cases of publication misconduct seriously. When the journal faces suspected cases of research and publication misconduct such as redundant (duplicate) publication, plagiarism, fraudulent or fabricated data, changes in authorship, an undisclosed conflict of interest, ethical problems with a submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and so on, the resolution process will follow the flowchart provided by the Committee on Publication Ethics (http:// publicationethics.org/resources/flowcharts). The Editorial Board discusses and makes decisions regarding any suspected cases.

10. Publication Ethics

• http://www.e-enm.org/authors/ethics.php
• i. Journal policies on authorship and contributorship;
  All authors of the article should have contributed significantly according to the following four criteria: 1) substantial contributions to the concept and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the work or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors should meet the above four conditions. For original articles, the specific contributions of each author must be described, and this information will be published in the Author Contributions section. After the initial submission of a manuscript, any changes whatsoever in authorship (adding author(s), deleting author(s), or rearranging the order of authors) must be explained by a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. Copyright assignment must also be completed by every author.
• ii. How the journal will handle complaints and appeals; EnM adheres to the COPE guidelines (https://publicationethics.org/appeals) regarding appeals to editorial decisions and complaints.
• iii. Journal policies on conflicts of interest / competing interests;
  The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors’ interpretation of the data. Examples of potential conflicts of interest are financial support from or connections to companies, political pressure from interest groups, and academically related issues. In particular, all sources of funding applicable to the study should be explicitly stated.
• iv. Journal policies on data sharing and reproducibility;
  EnM recommends that all submitted manuscripts that report the results of clinical trials adhere to the Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors (https://doi.org/10.3346/jkms.2017.32.7.1051; http://www.icmje.org/ recommendations)
• v. Journal's policy on ethical oversight;
  When the Journal faces suspected cases of research and publication misconduct such as a redundant (duplicate) publication, plagiarism, fabricated data, changes in authorship, undisclosed conflicts of interest, an ethical problem discovered with the submitted manuscript, a reviewer who has appropriated an author’s idea or data, complaints against editors, and other issues, the resolving process will follow the flowchart provided by the Committee on Publication Ethics (http://publicationethics.org/resources/flowcharts). The Editorial Board will discuss the suspected cases and reach a decision. We will not hesitate to publish errata, corrigenda, clarifications, retractions, and apologies when needed.
• vi. Journal's policy on intellectual property;
  All published papers become the permanent property of the Korean Endocrine Society. Copyrights of all published materials are owned by the Korean Endocrine Society.
• vii. Journal's options for post-publication discussions and corrections;
  The post-publication discussion is available through letter to editor. If any readers have a concern on any articles published, they can submit letter to editor on the articles. If there founds any errors or mistakes in the article, it can be corrected through errata, corrigenda, or retraction.

11. Publishing schedule

• http://www.e-enm.org/about/about.php
• It is published on a bimonthly basis.

12. Access

• http://www.e-enm.org/about/open_access.php
• This is an open access journal distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons. org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. .

13. Archiving

• It is accessible without barrier from PubMed Central (https://pubmedcentral.gov), Korea Citation Index (https://kci.go.kr), or National Library of Korea (http://nl.go.kr) in the event a journal is no longer published.

14. Revenue sources

• Revenue sources of journal were from the support of publisher (the Korean Endocrine Society).

15. Advertising

• EnM accepts advertisements on the following basis:
• i. Eligibility of the advertised products or services
• All products or services should be safe and reliable, and not cause any harm to the health and welfare of humans. Advertisements may promote information and technologies relevant for authors, editors, reviewers, and readers. Pharmaceutical products may also be considered.
• - Advertising is separate from content. Advertisers and sponsors have no advance knowledge of our editorial contents, nor do the editors have advance knowledge of advertisers. Content is never altered, added, or deleted to accommodate advertising. Advertisers and sponsors have no input regarding any of our editorial decisions or advertising policies.
• - Editorial board reserve the right to decline or cancel any advertisement at any time.
• - Advertisements for pharmaceutical products must conform to all regulations and policies of the Ministry of Food and Drug Safety, Republic of Korea in every respect.
• ii. Orders
• Any individuals or organizations who are interested in advertising their products or services in the print copies of the journal or on its website are encouraged to contact the editorial office. The acceptance of advertisement will be discussed by the editorial board and will be ultimately approved by the publisher.
• iii. Advertisement fee
• This academic journal and the advertisement price follow in accordance with the Korea Research-based Pharmaceutical Industry Association (KRPIA) Fair Competition Code and Working Guideline.
• iv. Disclaimer
• Liability: Neither the publisher nor the editors will be legally liable for advertisements presented in the journal. In addition, they cannot guarantee the accuracy, completeness, or usefulness of the information provided.
• Endorsement: The publisher and the editors do not endorse any products or services that are advertised.
• Disclaimer: Neither the publisher nor the authors will be legally liable for any of the content of advertisements, so readers must keep this in mind when reading or seeing advertisements.

16. Direct marketing

• Journal propagation has been done through the journal web site and distribution of an introduction pamphlet. Invitations to submit a manuscript are usually focused on the presenters at conferences, seminars, or workshops if the topic is related to the journal's aims and scope.